Last reviewed 2026-04-19 · How we verify

Ankylosing Spondylitis

Approved treatments

• Celebrex · Pfizer Inc. (originally Searle/Pharmacia)
  Celecoxib works by inhibiting COX-2 to reduce prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
• Cosentyx · Janssen Research & Development, LLC
• tumor necrosis factor inhibitors (TNFi) · Pfizer
• Solu-Cortef · Pfizer
• Abrilada · AbbVie
  Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors.
• Cortifoam · Pfizer
• Voltaren · Hisamitsu Pharmaceutical Co., Inc
• Cortone
• Celestone Soluspan
• Decadron · Generic (originally Merck)
• Reufenac
• Humira · AbbVie
  Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors.
• TNF Inhibitor · Pfizer
• Cosentyx · Novartis
  Secukinumab selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor.
• Indom · University of Trieste
• Cimzia · UCB
  Certolizumab pegol binds to and neutralizes human TNFα, reducing inflammation without causing antibody-dependent cell-mediated cytotoxicity.
• Remicade · Johnson & Johnson
  Infliximab binds to TNFα, blocking its interaction with receptors, reducing inflammation and immune responses.
• Remicade · Shanghai Biomabs Pharmaceutical Co., Ltd.
• prednison · Wen Zhang
• Remicade · Johnson & Johnson
  Infliximab-dyyb neutralizes TNFα by binding with high affinity to soluble and transmembrane forms, inhibiting receptor binding.
• CYLTEZO · BOEHRINGER INGELHEIM
• IXIFI · PFIZER INC
• Taltz · Yale University
• Medrol · Generic (originally Upjohn/Pfizer)
  Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions.
• Cortef · Generic (originally Merck/Upjohn)
• Hifenac
• Apazone
• Induction- PF-06480605 150 mg SC Q4W · Pfizer
  PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks.
• Rodinolone
• Deltasone · Generic (originally Schering)
• Indocin Sr
  Indomethacin works by blocking the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.
• Bay F 4975
  Acemetacin works by inhibiting the enzyme lactoylglutathione lyase, which is involved in the breakdown of certain inflammatory mediators.
• Arthrotec · Pfizer
• Simponi · Centocor Ortho Biotech Inc
  Simponi works by binding to tumor necrosis factor, preventing it from interacting with its receptors and thereby reducing inflammation.
• Taltz · Eli Lilly
  Humanized IgG4 monoclonal antibody that selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor.
• Tnkase · Roche
  Tenecteplase binds to fibrin and converts plasminogen to plasmin, enhancing fibrin-specific plasmin generation.
• Infliximab [infliximab biosimilar 3] · Pfizer
  Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions.
• Intra-articular corticosteroid injections · Pfizer
• Remicade · Johnson & Johnson
  Remicade works by binding to and neutralizing tumor necrosis factor, a protein that promotes inflammation and tissue damage.
• Enbrel · Immunex
  Enbrel works by binding to tumor necrosis factor, a protein that promotes inflammation, thereby reducing inflammation and alleviating symptoms.
• Betametasone
  Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system.
• Cortisol · University of Zurich
• Prelone · Generic (originally Schering)
• Cimzia · University of Washington
• celebrex · POZEN
• Simponi · Alvotech Swiss AG
• prednisolon · Hannover Medical School
• Metalyse · AO GENERIUM
• Humira · Sohag University
• Methylprednisolon · Leiden University Medical Center

Clinical guidelines

• FDA label — 2L
  XELJANZ tablets and XELJANZ XR (extended-release tablets) are indicated for the treatment of adult patients with active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers.
• FDA label — 2L
  XELJANZ tablets and XELJANZ XR (extended-release tablets) are indicated for the treatment of adult patients with active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers.
• FDA label — 1L|2L
  Reducing signs and symptoms in adult patients with active ankylosing spondylitis.
• FDA label — 2L
  reducing signs and symptoms in adult patients with active disease.
• FDA label — adj
  Dexamethasone is indicated as adjunctive therapy for short-term administration to tide the patient over an acute episode or exacerbation in ankylosing spondylitis.
• FDA label — 1L|2L
  Reducing signs and symptoms in adult patients with active ankylosing spondylitis.
• FDA label — 1L
  Secukinumab is indicated for the treatment of adult patients with active ankylosing spondylitis.
• FDA label — 1L
  Secukinumab is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
• FDA label — 2L
  XELJANZ tablets and XELJANZ XR (extended-release tablets) are indicated for the treatment of adult patients with active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers.
• FDA label — 2L
  Methylprednisolone can be used for the management of ankylosing spondylitis.
• FDA label — 2L
  Methylprednisolone can be used for the management of articular gout.
• FDA label — 2L
  Methylprednisolone can be used for the management of aspiration pneumonitis.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Ankylosing Spondylitis treatment landscape brief
• Ankylosing Spondylitis treatment updates RSS